Gelatin Patents (Class 424/456)
  • Patent number: 10842830
    Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Pendulum Therapeutics, Inc.
    Inventors: Colleen Cutcliffe, John S. Eid, James H. Bullard, Marcus F. Schicklberger
  • Patent number: 10813937
    Abstract: The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: October 27, 2020
    Assignee: Shenzhen Pharmacin Co., Ltd.
    Inventors: Zeren Wang, Jun Xu, Long Qu
  • Patent number: 10779561
    Abstract: A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, and at least one medium-chain triglyceride.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: September 22, 2020
    Assignee: AQUANOVA AG
    Inventor: Dariush Behnam
  • Patent number: 10758562
    Abstract: A supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals is disclosed. The supplement is in a gel form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise a vegetable oil, B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. The amount of mastic gum is from about 1 to about 6 grams per 10 cubic centimeters of gel.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 1, 2020
    Assignee: KAECO Group, Inc.
    Inventors: Kelly Terry, Leon Kratochvil, James Harless, Tom Kratochvil
  • Patent number: 10744131
    Abstract: Disclosed are abuse resistant oral pharmaceutical compositions that reduce the likelihood of improper administration of drugs that are susceptible to abuse. The oral pharmaceutical formulations contain abuse deterrent agents that cause discomfort to the user when administered in an improper manner and make the extraction of an active ingredient more difficult. Methods of making and using the compositions are also disclosed.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: August 18, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Harpreet Kaur Sandhu, Siva Ram Kiran Vaka, Ashish Chatterji, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Patent number: 10744101
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 18, 2020
    Assignee: Epizon Phama, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10744102
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 18, 2020
    Assignee: Epizon Pharma, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10736843
    Abstract: Methods of enhancing cognition and/or memory and methods of treating cognitive and cerebrovascular disorders by intranasally administering an in situ gelling composition comprising micelles formed with tocopherol or a derivative thereof are provided. The micelles encapsulate a biological active agent such as vinpocetine. The methods provide for enhanced brain targeting of the biological active agent.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 11, 2020
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Tarek A. Ahmed, Khalid M. El-Say, Osama A. A. Ahmed, Bader M. Aljaeid
  • Patent number: 10722527
    Abstract: Abiraterone acetate lipid formulations.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: July 28, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Hywel Williams, Prashant Agarwal, Eduardo Jule
  • Patent number: 10688066
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: June 23, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10688097
    Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 23, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li
  • Patent number: 10675276
    Abstract: The present invention relates to two novel oral pharmaceutical compositions of dabigatran etexilate or its pharmaceutically acceptable salts thereof, and the processes of preparation thereof.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: June 9, 2020
    Assignee: HANGZHOU SOLIPHARMA CO., LTD.
    Inventors: Xiaoxia Sheng, Yong Tang
  • Patent number: 10660859
    Abstract: The present disclosure relates to a novel aqueous coating composition comprising a polymer, at least one glidant, and at least one emulsifier, and at least one plasticizer, for soft capsule shells or softgel capsules, providing an enteric release profile, and to a method of enteric coating of soft capsule shells or containers; and to the resulting enteric coated soft capsule shells or softgel capsules with the aqueous coating composition.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 26, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Jan Vertommen, Marie Sophie Martina
  • Patent number: 10662120
    Abstract: A process for providing fluoresence to a dental ceramic body by treating at least a portion of the outer surface of the dental ceramic body or a precursor thereof with a bismuth containing substance, characterized by the steps of placing the dental ceramic body or the precursor thereof into a closeable container, in particular a crucible; generating a bismuth containing atmosphere in the container and exposing at least a portion of the outer surface of the dental ceramic body or of the precursor to the bismuth containing atmosphere at a temperature above 1000° C.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: May 26, 2020
    Assignee: STRAUMANN HOLDING AG
    Inventors: Alexander Zwahlen, Marc Stephan
  • Patent number: 10646495
    Abstract: Testosterone ester triglyceride formulations, optionally further including adducts. Methods of in-situ control of the manufacture or formation of such adducts are also described.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 12, 2020
    Assignee: Antares Pharma, Inc.
    Inventor: Shaowei Ong
  • Patent number: 10617761
    Abstract: The invention relates to polysiloxanes contained as defoaming agents, amongst other things, in medicinal compositions such colon cleansing solutions and antiflatulants. The aim of the invention is to further improve the defoaming effect of polysiloxanes and also the compatibility of the agents. According to the invention, the use of calcium sulphate increases the defoaming effect of dimeticon or simeticon as polysiloxane defoaming agents. The invention also relates to PEG-containing colon cleaning solutions based thereon.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 14, 2020
    Assignee: REGALISMONS S.A.
    Inventor: Uwe Willi Albrecht
  • Patent number: 10617699
    Abstract: The present invention relates to an orally administrable pharmaceutical dosage form for use in the prevention and/or treatment of a cardiovascular disease which includes (a) acetylsalicylic acid as a first active agent and (b) HMG-CoA reductase inhibitor as a second active agent. The HMG-CoA reductase inhibitor is selected from atorvastatin and rosuvastatin and salts thereof. The present invention is formulated in (a) two or more single separate coated dosage units in which the coating includes one or more water-soluble polymer and no more than 0 to 5% by weight of the coating of water-insoluble or enteric polymer, and in which the dosage units include 8 to 12 mg/cm2 coating and show an immediate release profile; and (b) one or more single separate coated dosage units.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: April 14, 2020
    Assignees: FERRER INTERNACIONAL, S.A., FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
    Inventors: Pablo Martin Sanz, Javier Urbano Hurtado
  • Patent number: 10576118
    Abstract: Methods of improving or enhancing sexual conditions in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are described. Methods of improving sexual functions, preventing further decline of sexual hormones, and/or improving sexual hormonal level in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are also described.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 3, 2020
    Assignee: GE Nutrients, Inc.
    Inventors: Sunil Bhaskaran, Ramasamy Varadarajan Venkatesh, Jith Veeravalli
  • Patent number: 10537562
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 21, 2020
    Assignee: Jubilant Generics Limited
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Patent number: 10525018
    Abstract: The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 7, 2020
    Assignee: FAES FARMA, S.A.
    Inventors: Josep María Suñé Negre, Ignacio Ortega Azpitarte, Pepa Del Arenal Barrios, Gonzalo Hernández Herrero
  • Patent number: 10526238
    Abstract: A method of forming a dissolvable part of amorphous borate includes: preparing a mixture comprising one or more boron compounds and one or more alkali compounds, at least one of the one or more boron compounds and the one or more alkali compounds being hydrous; heating the mixture to a melting temperature for a predetermined time to melt the mixture and release water from the mixture to form an anhydrous boron compound that is moldable, wherein the amount of alkali compound being selected to achieve an alkali oxide content of between about 10 to 25%; with the anhydrous boron compound at a molding temperature, molding the anhydrous boron compound in a mold; and cooling the anhydrous boron compound to form a solid.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: January 7, 2020
    Assignee: 1824930 Alberta Ltd.
    Inventors: Wesley Wall, Adam Wall, Ray Whitaker
  • Patent number: 10493065
    Abstract: Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 3, 2019
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Patrick Laughlin Mclean
  • Patent number: 10485753
    Abstract: Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: November 26, 2019
    Assignee: SpecGX LLC
    Inventors: Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
  • Patent number: 10449070
    Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 22, 2019
    Assignees: Kinki University, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshimasa Ito
  • Patent number: 10363254
    Abstract: Methods for treating or prophylaxis of a Cryptosporidium infection using compositions comprising a structure disclosed herein. Also provided are pharmaceutical compositions and kits for alleviating the symptoms of, for treating, or for preventing the occurrence of Cryptosporidium infection. The kits comprise one or more compounds having a structure disclosed herein, such as in an oral composition, and instructions for use, storage, and the like.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: July 30, 2019
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher D. Huston, Kovi Bessoff, Rajiv Satish Jumani
  • Patent number: 10245273
    Abstract: Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 2, 2019
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Wael Salameh, Panayiotis Constantinides
  • Patent number: 10212957
    Abstract: Disclosed in the present invention is a method for preparing an oil-dispersible carotenoid preparation, comprising (by weight parts): mixing 100 parts of carotenoid microcapsule, 100-400 parts of vegetable oil and 0.1-1 part of oil-soluble antioxidant; and grinding the mixture in a colloid mill in a nitro—gen atmosphere and at 10-30° C. to obtain a uniform oil-dispersible carotenoid preparation, wherein the preparation contains 2%-14% carotenoid with an average particle size of up to 0.1-1 ?m, and 100 parts of carotenoid microcapsule contains 10.5-35.8 parts carotenoid, 0.1-1 part of water-soluble antioxidant, and the remainder is a water-soluble colloid. The advantages of the present invention lie in that the oil-dispersible form has a high stability as the surface of the carotenoid particles is still protected with a dense water-soluble colloid, and that an oil-dispersible carotenoid preparation containing carotenoid with a content of up to 2%-14% and an average particle size of only 0.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: February 26, 2019
    Assignees: ZHEJIANG UNIVERSITY, ZHEJIANG NHU COMPANY LTD.
    Inventors: Dan Qiu, Lifang Shi, Jiandong Li, Zhirong Chen, Jiachao Zhou
  • Patent number: 10206971
    Abstract: Disclosed herein are methods of formulating cyclosporin A Form 2.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Prem Swaroop Mohanty, E. Quinn Farnes
  • Patent number: 10072311
    Abstract: The invention relates to novel Lactobacillus strains isolated from sourdough. Also encompassed is a composition comprising at least one of said Lactobacillus strains with optionally additional other microorganisms such as bacteria and/or yeasts. The invention further relates to the use of said Lactobacillus strains or compositions for the manufacture of human food products and food supplement products or animal feed products. Another aspect of the invention is the use of the Lactobacillus strains or the composition of Lactobacillus strains in human or veterinary medicine or in cosmetics.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: September 11, 2018
    Assignee: Ludwig Stocker Hofpfisterei GmbH
    Inventor: Jürgen Mayer
  • Patent number: 9993560
    Abstract: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: June 12, 2018
    Assignee: CIPLA Limited
    Inventors: Maruti Ganpati Ghagare, Sunilkumar Parasnath Saroj, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Patent number: 9982264
    Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 29, 2018
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 9949916
    Abstract: A non-irritating personal lubricant composition comprises a silicone fluid carrier and at least one sensorial agent, the composition having a viscosity of at least 175 centistokes.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: April 24, 2018
    Assignee: Church & Dwight Co., Inc.
    Inventors: Ovidiu Romanoschi, Jason R. Kieke, Michael J. Harrison, Luis Muniz
  • Patent number: 9938485
    Abstract: Compositions for increasing corn oil recovery and embodiments of methods for using the composition for corn oil separation are described. The composition(s) incorporate an admixture that includes a polymer selected from a polyglycol ester, a polyethyleneoxide-polypropyleneoxide block copolymer, a poloxamine, or a mixture thereof. The methods include admixing the compositions with a process stream for, for example, the extraction of oil from milled corn and residues from a fermentation step, including stillage (e.g., thin stillage or mid stillage), distiller's wet grain, distiller's dry grain and distiller's dry grains with solubles.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 10, 2018
    Assignees: Polymer Venture Inc., Phibro Animal Health Co.
    Inventors: Christopher B. Murphy, David A Fowlie
  • Patent number: 9925138
    Abstract: The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: March 27, 2018
    Assignee: Handa Pharmaceuticals, LLC
    Inventor: Fangyu Liu
  • Patent number: 9907789
    Abstract: Provided is a sustained-release preparation containing pioglitazone or a salt thereof as an active ingredient and showing superior sustainability. A sustained-release preparation containing pioglitazone or a salt thereof, which shows a dissolution ratio of pioglitazone of average 25-58% at the 2-hour time point, and average 60-100% at the 4-hour time point, in a dissolution test according to the 50 rpm USP Paddle Method and using pH 2.0 KCl/HCl buffer at 37° C. as a test solution.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 6, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yutaka Tanoue, Yusuke Murakawa, Yumiko Ishii, Kaoru Takenaka
  • Patent number: 9889152
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: February 13, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Patent number: 9795617
    Abstract: A hormone delivery system and method are provided for administering bioidentical human hormones using a combination of modalities for the treatment of human physiological conditions.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: October 24, 2017
    Assignee: Baucom Institute for Longevity and Life Enhancement, Inc.
    Inventor: Karan Y. Baucom
  • Patent number: 9775814
    Abstract: Described herein are enteric soft capsules comprising gastric resistant polymers and gelatin and methods for manufacturing the same. The enteric soft capsules described herein have enhanced enteric and elastic properties and are simpler to manufacture and produce.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 3, 2017
    Assignee: PATHEON SOFTGELS INC.
    Inventors: Helena Maria de Albuquerque Ferreira Teles, Henricus Marinus Gerardus Maria van Duijnhoven, Mélanie Françoise Géraldine Bayarri
  • Patent number: 9744182
    Abstract: Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B6, vitamin B12, Vitamin E, Vitamin C, iodine, iron, and magnesium. Described herein are manufactured dietary supplements that contain a phospholipid extract that contain phospholipid-DHA.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 29, 2017
    Assignee: Buriva, LLC.
    Inventors: Rhett Sean Daniels, Brett B Bartel
  • Patent number: 9730885
    Abstract: Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 15, 2017
    Assignee: Mallinckrodt LLC
    Inventors: Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
  • Patent number: 9717678
    Abstract: A delivery system for administration to a patient of Fenobam, its hydrates, and salts optimizes solubility and dissolution properties of Fenobam, its hydrates, and salts using either microemulsions, solid dispersions, cyclodextrin, gastroretentives, enteric coatings, and sustained delivery techniques to provide a vehicle for oral administration of these drugs.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: August 1, 2017
    Assignee: MURTY PHARMACEUTICALS, INC.
    Inventors: Santos B Murty, Ram B Murty
  • Patent number: 9661844
    Abstract: Vehicles for delivery and release of pesticide compositions are provided. In one aspect, the delivery vehicle is a capsule configured to resist release of a pesticide composition before application of the capsule at a locus where pest control is desired. The capsule is further configured to degrade following application at the locus where pest control is desired to facilitate release of the pesticide composition. In one particular but non-limiting form, the capsule includes a shell wall including a relatively high Bloom strength gelatin material and a plasticizer material, and the pesticide composition includes a fumigant such as 1,3-dichloropropene. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description and drawings.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 30, 2017
    Assignee: Dow AgroSciences LLC
    Inventors: Lorenzo Aulisa, John D. Busacca, Donald E. Williams, III, Phillip J. Howard, Ashish Batra, Sara J. Linder
  • Patent number: 9592200
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: March 14, 2017
    Assignee: COLLEGIUM PHARMACEUTICAL, INC.
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
  • Patent number: 9579227
    Abstract: An orally administrable implement for expanding in a stomach of an animal, including a mammal, to fill a space in the stomach, is provided for weight control. The implement includes: a fluid-permeable expandable container having a first dimension and a second dimension; and a plurality of clusters comprising a swellable material contained within the container and capable of swelling when contacted with a fluid; whereby when the implement is ingested, the fluid in the stomach enters the container causing the clusters therein to swell and the container to expand from the first dimension to the second dimension.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: February 28, 2017
    Assignee: EAT LITTLE INC.
    Inventors: Martin Mintchev, Orly Yadid-Pecht, Michel Fattouche
  • Patent number: 9579383
    Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: February 28, 2017
    Assignee: ALA WAI PHARMA, INC.
    Inventors: Eric Holmes, Michael Hite
  • Patent number: 9522109
    Abstract: A method for enhancing skin collagen in an individual includes administering a composition to the individual, the composition comprising a skin collagen enhancing agent comprising menaquinone-7 as an active ingredient. In addition, a composition is provided in the form of at least one of an emulsion and a cream, the composition including a skin collagen enhancing agent comprising menaquinone-7 as an active ingredient.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: December 20, 2016
    Assignee: J-Oil Mills, Inc.
    Inventors: Toshiro Sato, Rumi Kawahara, Shuichi Kamo
  • Patent number: 9452150
    Abstract: A composition in which a preparation of the composition itself has an excellent disintegratability in the right place and excellent active ingredient releasability within the digestive tract, the active ingredient and the preparation itself have long-term stability, excellent ease of operation such as manufacturability and filling into containers, an amount sufficient for achieving physiological effects can be easily taken and swallowed, and can be absorbed rapidly from the digestive tract, thus the physiological effect can be expected. The composition is an easy-release jelly composition containing an emulsified polyvalent unsaturated fatty acid or derivative thereof in an amount exceedingly 10 mass % and further containing an emulsifying agent and a gallant. The easy-release jelly composition includes an emulsified polyunsaturated fatty acid or derivative thereof in an amount greater than 10 wt %, an emulsifying agent, and a gelling agent.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: September 27, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki Ueshima, Shigeharu Suzuki, Naomi Yokomizo, Atsushi Sato, Hirosato Fujii
  • Patent number: 9439851
    Abstract: The present invention provides a novel gastric retention system in the form of a tablet or a capsule coated with an expandable coating, more particularly, with an expandable coating comprising a film-forming polymer and an expandable component.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: September 13, 2016
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadhkari, Yashoraj Rupsinh Zala
  • Patent number: 9427012
    Abstract: A softgel capsule containing microencapsulated probiotic bacteria is manufactured such that the softgel capsule is stable for at least about 24 months at room temperature.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: August 30, 2016
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Claudia Valla, Rosa Bertolami, Giovanni Rosina, Karen Helson
  • Patent number: RE47316
    Abstract: This invention relates to a liquid or semisolid oral drug formulation comprising a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: March 26, 2019
    Assignee: QUATRX PHARMACEUTICALS COMPANY
    Inventors: Veli-Matti Lehtola, Markku Anttila